• 1
    Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell based anti-cancer vaccines. Immunol Rev. 2008; 222: 256-267.
  • 2
    Rosenberg S, Yang J, Restifo N. Cancer Immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10: 909-915.
  • 3
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 1451-1467.
  • 4
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet. 2005; 365: 1687-1717.
  • 5
    Hackshaw A, Roughton M, Forsyth S, et al. Long-Term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol. 2011; 29: 1657-1663.
  • 6
    Perou C, Sorlie T, Eisen M, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
  • 7
    Sorlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
  • 8
    Nielson T, Hsu F, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
  • 9
    Cheang M, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by 5 biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14: 1368-1376.
  • 10
    Chen Y, DeVries S, Anderson J, et al. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer. 2009; 18: 285-294.
  • 11
    Xu S, Koldovsky U, Xu M, et al. High avidity antitumor T cell generation by toll receptor 8-primed, myeloid-derived dendritic cells is mediated by IL-12 production. Surgery. 2006; 140: 170-178.
  • 12
    Xu S, Koski G, Faries M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12 dependent mechanism. J Immunol. 2003; 171: 2251-2261.
  • 13
    Schmidt C, Mescher M. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J Immunol. 2002; 68: 5521-5529.
  • 14
    Czerniecki B, Koski G, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007; 76: 1842-1852.
  • 15
    Perez S, Sotiropoulou P, Sotiriadou N, et al. HER-2/neu-derived peptide 884-889 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones. Cancer Immunol Immunother. 2002; 50: 615-624.
  • 16
    Roses R, Paulson E, Sharma A, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1386-1389.
  • 17
    Hynes N, Stern D. The biology of erb-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta. 1994; 1198: 165-184.
  • 18
    Hynes N, Gerber H, Saurer S, et al. Overexpression of the c-erb-2 protein in human breast tumor cell lines. J Cell Biochem. 1989; 39: 167-173.
  • 19
    Hynes N. Amplification and overexpression of the erb-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol. 1994; 4: 19-26.
  • 20
    Pegram M, Finn R, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 1997; 15: 537-547.
  • 21
    Kakarala M, Wicha M. Implications of the cancer stem cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008; 26: 2813-2820.
  • 22
    Korkaya H, Paulson A, Lovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008; 27: 6120-6130.
  • 23
    Koski G, Koldovsky U, Xu S, et al. A novel dendritic cell based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012; 35: 54-65.
  • 24
    Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003; 21: 3826-3835.
  • 25
    Kobayashi H, Wood M, Song Y, et al. Defining promiscuous MHC class II helper T cell epitopes for the HER-2/neu tumor antigen. Cancer Res. 2000; 60: 5228-5236.
  • 26
    Knutson K, Schiffman K, Cheever M, et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide specific immunity. Clin Cancer Res. 2002; 8: 1014-1018.
  • 27
    Bahl S, Roses R, Sharma A, et al. Asymptomatic changes in cardiac function can occur in ductal-carcinoma-in-situ patients following treatment with HER-2/neu pulsed dendritic cell vaccine. Am J Surg. 2009; 198: 488-494.
  • 28
    Burge C, Chang H, Apple S. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical specimens? Breast. 2006; 15: 167-172.
  • 29
    Tamimi R, Baer H, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008; 10: R67.
  • 30
    Kristensen VN, Vaske CJ, Ursini-Siegel J, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA. 10.1073/PNAS. 1108781108.
  • 31
    Horiquchi J, Oyama T, Takata D, et al. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. Anticancer Res. 2011; 31: 3041-3046.
  • 32
    Ring A, Smith I, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004; 91: 2012-2017.
  • 33
    Arpino G, Wiechmann L, Osborne C, et al. Crosstalk between the estrogen receptor status and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008; 29: 217-233.
  • 34
    Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-postive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
  • 35
    Dent R, Clemons M. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence. Cancer Treat Rev. 2006; 32: 144-148.
  • 36
    Bedrosian I, Hu C, Chang G. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010; 102: 401-409.
  • 37
    Schiff R, Massarweh S, Shou J, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004; 10: 331s-336s.
  • 38
    Nahta R, Esteva F. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006; 232: 123-138.
  • 39
    Haffy B, Yang Q, Reiss M, et al. Loco-regional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. J Clin Oncol. 2006; 24: 5652-5657.